Amphastar Pharmaceuticals AMPH Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's finance lease liabilities?
- Amphastar Pharmaceuticals (AMPH) reported finance lease liabilities of $232K in Q1 2026.
- How has Amphastar Pharmaceuticals's finance lease liabilities changed year-over-year?
- Amphastar Pharmaceuticals's finance lease liabilities decreased by 39.3% year-over-year, from $382K to $232K.
- What is the long-term trend for Amphastar Pharmaceuticals's finance lease liabilities?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's finance lease liabilities has grown at a -15.4% compound annual growth rate (CAGR), from $610K to $264K.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.